Surgical treatment of macular holes with and without the use of autologous platelet-rich plasma
- PMID: 33392943
- DOI: 10.1007/s10792-020-01662-4
Surgical treatment of macular holes with and without the use of autologous platelet-rich plasma
Abstract
Purpose: To compare the results of treatment of idiopathic full-thickness macular holes (MHs) with and without the use of autologous platelet-rich plasma (APRP).
Methods: This partially retrospective study included 152 patients (152 eyes) with MHs operated in the years 2010-2014 using conventional technology with internal limiting membrane peeling (control group) and 62 patients (62 eyes), operated by the same surgeons in 2015-2017 with additional application of APRP on MH (platelet group). Pre and postoperative best-corrected visual acuities (BCVA) were recorded, and retinal microstructure was studied using optical coherence tomography. Thirty-seven patients in the platelet group and 80 controls were followed for at least 12 months (for visual outcomes 15 controls were followed for 15-24 months). The data of 72 controls (72 eyes) were analyzed retrospectively.
Results: The minimum diameter of the MH in the platelet group was larger than in controls: 454 ± 186 vsersus 381 ± 148 μm (P = 0.003). Despite this, all MHs in the platelet group were closed, while in the control group 11 holes (7.2%) remained open (P = 0.036). The final mean BCVA, standardized by the minimum diameter of the macular hole, was higher in the platelet group by 3.9 ETDRS letters (P = 0.012). After surgery with APRP, foveal hyperreflective lesion (presumably glial proliferation) was found, which persisted in most large MHs, but gradually disappeared in small and most medium MHs.
Conclusion: The use of APRP significantly improves the anatomical and functional results of treatment of idiopathic MHs. In very large MHs, APRP presumably enhances glial proliferation, which ensures their closure.
Keywords: Anatomical outcome; Idiopathic macular hole; Optical coherence tomography; Platelet-rich plasma; Surgery; Visual acuity.
References
-
- Gaudric A, Massin P, Paques M, Santiago PY, Guez JE, Le Gargasson JF, Mundler O, Drouet L (1995) Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol 233(9):549–554. https://doi.org/10.1007/BF00404704 - DOI - PubMed
-
- Paques M, Chastang C, Mathis A, Sahel J, Massin P, Dosquet C, Korobelnik JF, Le Gargasson JF, Gaudric A (1999) Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology 106(5):932–938. https://doi.org/10.1016/s0161-6420(99)00512-6 - DOI - PubMed
-
- Vote BJ, Membrey WL, Casswell AG (2004) Autologous platelets for macular hole surgery: the Sussex Eye Hospital experience. Clin Experiment Ophthalmol 32(5):472–477. https://doi.org/10.1111/j.1442-9071.2004.00866.x - DOI - PubMed
-
- Cheung CMG, Munshi V, Mughal S, Mann J, Hero M (2005) Anatomical success rate of macular hole surgery with autologous platelet without internal-limiting membrane peeling. Eye 19(11):1191–1193. https://doi.org/10.1038/sj.eye.6701733 - DOI - PubMed
-
- Kapoor KG, Khan AN, Tieu BC, Khurshid GS (2012) Revisiting autologous platelets as an adjuvant in macular hole repair: chronic macular holes without prone positioning. Ophthalmic Surg Lasers Imaging 43(4):291–295. https://doi.org/10.3928/15428877-20120426-03 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
